Efficacy of Brexpiprazole on Neuropsychiatric Symptoms and Impact on Caregivers: Pooled Neuropsychiatric Inventory (NPI) Analysis in Patients With Agitation Associated With Dementia due to Alzheimer's Disease.
George T Grossberg, Marwan N Sabbagh, Sanjeda R Chumki et al.
✦ AI-curated · Sources linked
In 30 seconds
This exploratory pooled analysis examined Neuropsychiatric Inventory (NPI) outcomes from two randomized, double-blind, placebo-controlled trials of brexpiprazole for agitation associated with Alzheimer’s disease dementia. Among participants receiving brexpiprazole 2 or 3 mg/day (N = 368) versus placebo (N = 253), scores improved more with brexpiprazole for agitation/aggression from Week 6 onwards and for related caregiver distress and occupational disruption from Week 4 onwards. Greater improvements were also reported for several other neuropsychiatric symptoms and their caregiver impact over 12 weeks.
Key findings
- Brexpiprazole 2 or 3 mg/day (N = 368) improved NPI agitation/aggression scores more than placebo (N = 253) from Week 6 onwards.
- Associated occupational disruptiveness/caregiver distress scores improved more with brexpiprazole than placebo from Week 4 onwards.
- Greater improvements were also reported for irritability/lability, aberrant motor behavior, and anxiety, including associated caregiver-impact scores.
Why it matters
Agitation and other behavioral symptoms in Alzheimer’s disease dementia can affect both patients and caregivers. These pooled trial findings suggest that symptom improvement with brexpiprazole may extend beyond agitation/aggression to other measured neuropsychiatric symptoms and caregiver disruption, providing a broader view of outcomes assessed in the trials.
What to keep in mind
This was an exploratory pooled analysis of NPI data from two trials; the abstract provides no effect sizes or detailed statistical results.